News

This HCPLive Five features advancements in asthma, immunology, and allergy that were presented at the ACAAI 2025 meeting in Orlando.

GLP-1 receptor agonists revolutionize treatment in cardiology, offering new hope for heart failure and related conditions beyond weight loss.

Investigators evaluated current prescription patterns for systemic HS medications among European HS specialists and opinions on criteria for biologic upgrades.

Gwarzo discussed the shortcomings faced by many patients with SCD during pain crises, due to less frequent opioid prescription than guidelines recommend.

In women with CKD, there are no general survival advantages compared to the male patient population.

Following its 2025 FDA approval, lumateperone 42 mg demonstrated meaningful reductions in MADRS and CGI-S scores in adults with major depressive disorder.

Announced by Cogent Biosciences, these data indicate bezuclastinib’s capacity for improving patient-reported symptoms of mast cell burden.

The approval of Ayrmid’s omidubicel-onlv makes it the first hematopoietic stem cell transplant therapy to treat patients with severe aplastic anemia.

Mallon explains the shared risks linking celiac disease and type 1 diabetes and why early screening improves outcomes.

A retrospective cohort in finerenone showed nearly 40% proteinuria reduction at 8 months and stable eGFR in patients with IgA nephropathy.

This systematic review and meta-analysis looked at research on the efficacy and safety of topical roflumilast 0.3% in patients with plaque psoriasis.

Oral bradykinin B2 receptor antagonist resolved HAE attacks in under 90 minutes, with most patients needing only a single dose and no rescue medication.

A longitudinal cohort study shows a lack of correlation between decreased proteinuria levels and improved treatment, renal responses in patients.

Rusfertide shows promising results as a first-in-class therapy for polycythemia vera, demonstrating sustained hematocrit control and safety in recent studies.

Catch up with major trial results, key clinician insights, and more.

Explore the latest advancements in kidney stone treatment, focusing on suction technology and its impact on surgical outcomes and patient safety.

This FDA News Month in Review provides a round-up of regulatory decisions from November 2025.

Cohen cites past failures with risk-based hepatitis B vaccination and voices concerns about the CDC APIC vote for individual-based decision-making.

As the FDA strengthens AI standards after its recent meeting, a new AI-assisted genetic tool shows promise for pinpointing patients who may respond to a vasopressin blocker.

The 8-3 APIC vote recommends individual-based decision-making for HBV vaccination in infants born to women who test negative for the virus.

Decreased serum albumin levels can be a tool for predicting the risk of cancer and mortality in patients undergoing hemodialysis.

Remote patient monitoring revolutionizes cardiovascular care, enhancing preventive strategies, patient engagement, and outcomes through advanced technology and AI integration.

Findings suggest people with reduced kidney function have higher levels of Alzheimer’s biomarkers in their blood but not an increased risk of dementia.

This randomized study explored a lower-cost, ambient-light, nonpolarized dermatoscope and its clinical utility in patient-performed teledermoscopy.

As mental health AI tools rise, the FDA weighs benefits and risks, emphasizing oversight and performance testing. Eriksson discusses AI in psychiatric care.

This special edition episode explores the advancements in incretin therapies that defined 2025.

This summary of an SDPA Fall session highlights data on the skin microbiome and its impact on dermatologic diseases such as atopic dermatitis.

A survey found many obstetric physicians rarely refer pregnant patients for allergy or immunology care, citing knowledge gaps and long wait times.